Catalent, Inc. (NYSE:CTLT) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC trimmed its stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 1.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,265,795 shares of the company's stock after selling 44,869 shares during the period. Geode Capital Management LLC owned 2.35% of Catalent worth $257,498,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Nisa Investment Advisors LLC lifted its stake in Catalent by 1.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company's stock valued at $619,000 after buying an additional 185 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Catalent by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company's stock valued at $1,179,000 after acquiring an additional 220 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Catalent by 2.6% in the third quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company's stock valued at $553,000 after acquiring an additional 229 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Catalent by 3.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company's stock worth $432,000 after acquiring an additional 278 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Catalent by 26.9% during the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company's stock worth $79,000 after purchasing an additional 278 shares in the last quarter.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CTLT. StockNews.com cut shares of Catalent from a "hold" rating to a "sell" rating in a research note on Tuesday, December 10th. Robert W. Baird restated a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to data from MarketBeat, Catalent currently has a consensus rating of "Hold" and an average target price of $63.40.

Catalent Trading Up 0.0 %

NYSE:CTLT traded up $0.02 on Friday, reaching $63.07. The company's stock had a trading volume of 1,201,964 shares, compared to its average volume of 2,071,804. Catalent, Inc. has a 12-month low of $40.29 and a 12-month high of $63.25. The stock has a 50 day moving average price of $60.30 and a 200 day moving average price of $59.04. The firm has a market cap of $11.45 billion, a price-to-earnings ratio of -27.91, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the previous year, the firm earned ($0.10) EPS. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. On average, equities analysts anticipate that Catalent, Inc. will post 0.78 EPS for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.